Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 1.00 |
| ▸ | HTR1D | P28221 | 19/20 | 1.00 |
| ▸ | HTR1B | P28222 | 18/20 | 1.00 |
| ▸ | HTR7 | P34969 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565044 | 0.90 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL6832015 | 0.87 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL5344886 | 0.87 | HTR1A (0.77) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL6826131 | 0.86 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL6833678 | 0.83 | HTR1A (0.96) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL5213744 | 0.82 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL14564979 | 0.82 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL6828921 | 0.81 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL5216805 | 0.80 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 | |
| SCHEMBL29388787 | 0.80 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | HTR1A 971/4885HTR1D 958/4885HTR1B 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.